本文選題：I型人免疫缺陷病毒 + 人獲得性免疫缺陷綜合征　； 參考：《第四軍醫(yī)大學(xué)》2006年博士論文

【摘要】：獲得性免疫缺陷綜合征(AIDS)絕大多數(shù)是由Ⅰ型人類免疫缺陷病毒(HIV-1)引起的全球流行的傳染病，并成為人類主要的致死性疾病之一。據(jù)2005年聯(lián)合國(guó)艾滋病規(guī)劃署和世界衛(wèi)生組織的最新估計(jì)，自1981年首次發(fā)現(xiàn)HIV-1感染者以來(lái)，全球感染者累計(jì)7，000萬(wàn)人以上，現(xiàn)存人數(shù)4，，030萬(wàn)，每年約新增感染者490萬(wàn)。高效抗逆轉(zhuǎn)錄病毒療法(HAART)雖能降低部分患者病毒含量，延緩病情發(fā)展，改善癥狀，但因費(fèi)用高、藥物副作用大使許多患者難以耐受，也不能為大多數(shù)患者接受(特別是發(fā)展中國(guó)家患者)，更為重要的是HAART不能完全清除病毒。所以尋找有效HIV-1疫苗是目前迫切解決的問(wèn)題。大量研究證明細(xì)胞免疫特別是HIV-1特異性CTL應(yīng)答反應(yīng)在控制HIV-1感染中起關(guān)鍵作用。故研發(fā)以增強(qiáng)HIV-1特異性CTL效應(yīng)為目的的疫苗具有很大潛力。開發(fā)此類疫苗首要的任務(wù)是確定能誘導(dǎo)強(qiáng)的HIV-1特異性CTL應(yīng)答并具有廣泛免疫原性的特異性表位。有效的HIV-1特異性CTL應(yīng)答不僅由抗原結(jié)構(gòu)決定，同時(shí)受到HLA-Ⅰ等位基因限制，可見，篩選和鑒定具有強(qiáng)的和廣泛作用的HIV-1特異性CTL表位其中研究表位的HLA-Ⅰ類分子限制性是不可缺少的工作。不同人群HLA-Ⅰ等位基因的分布頻率不同，決定不同人群對(duì)HIV-1的CTL應(yīng)答模式不同，所以在不同人群開展HIV-1特異性
[Abstract]:Acquired immunodeficiency syndrome (AIDS), the overwhelming majority of the global epidemic caused by the type I human immunodeficiency virus (HIV-1), has become one of the major fatal diseases of human beings. According to the latest estimates of the United Nations AIDS programme and the WHO in 2005, the global sense of the first discovery of HIV-1 infected people since the first discovery in 1981 The total number of infected people is more than 70 million, the number of existing people is 40 million 300 thousand, and the number of infected people is 4 million 900 thousand. High performance antiretroviral therapy (HAART) can reduce the virus content of some patients, delay the development of the disease, improve the symptoms, but because of the high cost, many patients are hard to tolerate the side effects of the drugs and can not be accepted for most patients (especially the development). The more important thing is that HAART can not completely remove the virus. So it is an urgent problem to find an effective HIV-1 vaccine. A large number of studies have shown that cellular immunity, especially the HIV-1 specific CTL response, plays a key role in controlling HIV-1 infection. Great potential. The primary task of developing such vaccines is to determine the specific epitopes that can induce strong HIV-1 specific CTL responses and have extensive immunogenicity. Effective HIV-1 specific CTL responses are not only determined by the antigen structure, but also by the HLA- I allele, which can be seen, screening and identifying the strong and extensive HIV-1 special. The CTL epitopes of the heterosexual epitopes are indispensable to study the HLA- I molecular restriction of the epitopes. The distribution frequency of HLA- I alleles in different populations determines the different CTL response patterns of different populations to HIV-1, so HIV-1 specificity is carried out in different populations.
【學(xué)位授予單位】：第四軍醫(yī)大學(xué)
【學(xué)位級(jí)別】：博士
【學(xué)位授予年份】：2006
【分類號(hào)】：R392

【參考文獻(xiàn)】

相關(guān)期刊論文 前2條

1 康來(lái)儀,潘啟超,莊鳴華;艾滋病防治研究進(jìn)展[J];海峽預(yù)防醫(yī)學(xué)雜志;2001年01期

2 王莉馨,金寧一,王宏偉,秦云龍,羅坤,葛濤,江文正,金洪濤;HIV-1中國(guó)流行株gag與hIL-2在重組痘苗病毒中的共表達(dá)及其與核酸疫苗的實(shí)驗(yàn)免疫研究[J];中國(guó)免疫學(xué)雜志;2002年05期

本文編號(hào)：2106878